Cervical Dystonia When First-Line BoNT-A Has Not Achieved Adequate Clinical Improvement
Cervical dystonia is managed with botulinum neurotoxin type A (BoNT-A) as the established first-line approach. When a patient does not show sufficient clinical improvement in the 4–6 weeks following injection, the protocol shifts to a structured reassessment and optimization process before any change in treatment strategy is determined.
Failure condition
First-line treatment with botulinum neurotoxin type A (BoNT-A) — individualized, with instrumental guidance and combination physiotherapy — was assessed between 4 and 6 weeks after injection. Adequate clinical improvement of cervical dystonia was not achieved, triggering escalation to this protocol.
Next-step approach (partial overview)
The protocol focuses on a systematic optimization of BoNT-A therapy before classifying the patient as a non-responder. This involves reassessment of dosing, muscle selection, and the use of instrumental guidance — with electromyographic evaluation playing a central role in identifying the muscles to target.
References
- Before defining non-response, clinicians should consider dose adjustments, muscle re-selection, the systematic use of instrumental guidance, and re-evaluation of the dystonic phenotype.
- In the poorly responsive or nonresponsive dystonic patient, a poly-EMG should be performed to identify the dystonic muscles to be treated.
- In case of partial or no response, it is necessary to reevaluate the patient clinically and instrumentally (poly-EMG).
DOI: 10.3390/toxins18020079
View source ↗